Navigation Links
Amphetamines reverse Parkinson's disease symptoms in mice

Amphetamines, including the drug popularly known as Ecstasy, can reverse the symptoms of Parkinson's disease in mice with an acute form of the condition, according to new research at Duke University Medical Center.

The researchers caution that the findings in animals do not suggest Parkinson's disease patients should find relief by taking amphetamines, which are drugs of abuse with many dangerous side effects. The findings rather indicate that drugs with similar chemical attributes might offer useful alternatives to current therapies, the researchers said.

The new study also shows that amphetamines -- normally thought to act by increasing dopamine concentrations in the brain ? correct the behavioral abnormalities associated with Parkinson's in mice devoid of the brain messenger. Dopamine normally acts on dopamine receptors ? protein switches on the surface of neurons -- to stimulate brain processes that affect movement, emotion, pleasure and mood.

Parkinson's disease stems from the degeneration of neurons in a brain region that controls movement. That degeneration, in turn, leads to a shortage of the chemical messenger dopamine. The finding that amphetamines can alter movement independently of dopamine opens up new directions in the search for prospective anti-Parkinsonian drugs, the researchers said.

The researchers, led by James B. Duke professor of cell biology Marc Caron, Ph.D. and Assistant Research Professor Raul Gainetdinov, M.D., Ph.D., of Duke, made the discovery after testing the utility of more than 60 compounds for reversing Parkinson's symptoms in a mouse model of the disease. Developed by the Duke team, the mice lack detectable brain levels of dopamine and experience essentially all the symptoms of Parkinson's disease for several hours before recovering their normal behavior. Caron is also a researcher of the Duke Institute for Genome Sciences & Policy.

The team reports its findings in the August 2005 issue of
'"/>

Source:Duke University Medical Center


Page: 1 2 3 4

Related biology news :

1. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
2. Genetic therapy reverses nervous system damage in animal model of inherited human disease
3. U of MN researchers reverse memory loss in mice
4. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
5. Researchers develop gene therapy to reverse pulmonary arterial hypertension
6. Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy
7. Stem cell microenvironment reverses malignant melanoma
8. Researchers reverse juvenile diabetes in animal model
9. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
10. Intensive statin therapy may partially reverse plaque build-up in arteries
11. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Amphetamines reverse Parkinson disease symptoms mice

(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... may soon be a boon to biofuels producers. The ... a surprisingly minimal repertoire of genes that it employs ... further improvements in enzymes customized for biofuels production. ... Biotechnology by a team of government, academic, and industry ...
... the public and the scientific community for access to ... copyright policy to allow authors to retain the rights ... which became effective May 1, applies to all three ... The Journal of Experimental Medicine and The Journal of ...
... (May 2, 2008)As the westernization of India accelerates, tobacco advertising ... urban Indian children as young as 11, according to a ... Public Health. , The study, Associations Between Tobacco Marketing ... the May/June issue of the American Journal of Health Behavior. ...
Cached Biology News:Lean and mean biomass-degrading fungus reveals capabilities for improved biofuel production 2Lean and mean biomass-degrading fungus reveals capabilities for improved biofuel production 3Rockefeller University Press allows authors to retain copyright to their published work 2UT researchers find link between advertising and increased tobacco use among India's youth 2UT researchers find link between advertising and increased tobacco use among India's youth 3
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Francois Vieillard as Sales & Marketing Director. , With more than 25 ... be responsible for reinforcing Tronics’ business development activities worldwide. He brings to the ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
(Date:7/30/2015)... ... , ... As part of its 2015 growth plan and as a follow up to the ... units, Whitehouse Laboratories is pleased to announce that it has begun construction on a new ... and will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... 15 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... sale of shares of convertible preferred stock pursuant to a ... proceeds of approximately $2 million. The preferred stock is convertible ... the investor at a price of $0.1105 per share. , ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... endocrine therapy and oncology, today reported that patient follow-up ... Phase 3 program in benign prostatic hyperplasia (BPH) with ... be completed at the end of this week. Therefore, ...
... Inc., an award-winning developer of Microfluidics and Live ... its cellTRAY Imaging System and cellTRAY Fluidics System ... Imaging and Fluidics Systems provide solutions to a ... reproductive technology (ART), stem cell research, and cryobiology, ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems 2
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Request Info...
...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: